What is the main purpose of this filing?

This filing is an amended 10-Q (Quarterly Report) for Johnson & Johnson, indicating that the company has updated or corrected previously submitted financial information for the quarter ending October 1, 1994.

Where can I find the actual financial results for Johnson & Johnson from this period?

The provided text contains only navigational elements and metadata about the SEC filing. To find the actual financial results, revenue, profit, and management discussion, you would need to access the full content of the 10-Q/A filing, typically available through the SEC's EDGAR database or financial data providers.

Why would Johnson & Johnson amend a quarterly report?

Companies amend reports to correct errors, provide updated information, or respond to SEC inquiries. This amendment suggests that there was a need for revised disclosures concerning their financial performance or other relevant aspects of the quarter ending October 1, 1994.

What key financial metrics should I look for in the full 10-Q filing?

Investors should look for details on revenue growth across JNJ's segments (Pharmaceuticals, Medical Devices, Consumer Products), net income, earnings per share (EPS), operating margins, cash flow from operations, and any significant changes in debt or equity. Also, pay attention to the Management's Discussion and Analysis (MD&A) for insights into business drivers and risks.

JNJ 10-Q Filed Dec 22, 1994

Summary

Johnson & Johnson's (JNJ) 10-Q/A filing for the period ending October 1, 1994, presents an amendment to their quarterly report. While the provided text is primarily navigational and technical information related to the SEC filing itself, it indicates that JNJ was actively reporting its financial status during this period. Investors would typically look to the full 10-Q document for crucial details on financial performance, including revenue, profitability, and segment performance across their diverse healthcare businesses (pharmaceuticals, medical devices, and consumer products). Any analysis would require accessing the actual financial statements and management's discussion and analysis within the full filing. This amendment suggests potential corrections or updates to previously filed information, underscoring the importance of reviewing the most current version of the report. Investors should focus on trends in sales, earnings per share, and any disclosures regarding significant events or risks that might impact future performance.

Key Highlights

1Amendment filed on December 21, 1994, for the quarterly period ending October 1, 1994.
2Indicates Johnson & Johnson's ongoing reporting of financial information to investors.
3The filing belongs to the Consumer Health Products, Pharmaceuticals, and Medical Devices segments.
4This filing is an amended 10-Q, suggesting updates or corrections to previously reported information.
5Provides an opportunity for investors to review revised financial disclosures for the period.

JOHNSON & JOHNSON Quarterly Report (Amendment) for Q3 Ended Oct 2, 1994

Summary

Key Highlights

Frequently Asked Questions